CN114874149A - 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法 - Google Patents

制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法 Download PDF

Info

Publication number
CN114874149A
CN114874149A CN202210565751.2A CN202210565751A CN114874149A CN 114874149 A CN114874149 A CN 114874149A CN 202210565751 A CN202210565751 A CN 202210565751A CN 114874149 A CN114874149 A CN 114874149A
Authority
CN
China
Prior art keywords
compound
dihydrochloride
slurry
polymorph
acetone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210565751.2A
Other languages
English (en)
Chinese (zh)
Inventor
C.贝茨
D.P.里德
毛建民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CN114874149A publication Critical patent/CN114874149A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202210565751.2A 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法 Pending CN114874149A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562268758P 2015-12-17 2015-12-17
US62/268758 2015-12-17
CN201680081965.5A CN108602779A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
PCT/US2016/067161 WO2017106639A1 (en) 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680081965.5A Division CN108602779A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法

Publications (1)

Publication Number Publication Date
CN114874149A true CN114874149A (zh) 2022-08-09

Family

ID=59057623

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680081965.5A Pending CN108602779A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
CN202210565751.2A Pending CN114874149A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680081965.5A Pending CN108602779A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法

Country Status (16)

Country Link
US (4) US9834519B2 (enExample)
EP (2) EP4015508A1 (enExample)
JP (2) JP6940504B2 (enExample)
KR (1) KR20180085814A (enExample)
CN (2) CN108602779A (enExample)
AU (2) AU2016369520B2 (enExample)
BR (1) BR112018012325A2 (enExample)
CA (1) CA3006077A1 (enExample)
EA (1) EA201891431A1 (enExample)
HK (1) HK1255014A1 (enExample)
IL (1) IL259557A (enExample)
MX (2) MX385672B (enExample)
NZ (1) NZ742785A (enExample)
SG (1) SG11201804601TA (enExample)
TW (1) TWI748972B (enExample)
WO (1) WO2017106639A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4015508A1 (en) * 2015-12-17 2022-06-22 ArQule, Inc. Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
AU2016369523B2 (en) 2015-12-17 2021-12-23 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
US10878412B2 (en) * 2019-05-13 2020-12-29 Truist Bank In-line verification of transactions
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
CN102325755A (zh) * 2008-12-30 2012-01-18 阿奎利公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
WO2015150900A2 (en) * 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
AU2005316312B2 (en) * 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
CA2710051C (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
EP4015508A1 (en) * 2015-12-17 2022-06-22 ArQule, Inc. Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
AU2016369523B2 (en) 2015-12-17 2021-12-23 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
CN102325755A (zh) * 2008-12-30 2012-01-18 阿奎利公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
WO2015150900A2 (en) * 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘新泳等: "《实验室有机化合物制备与分离纯化技术》", vol. 2011, 人民卫生出版社, pages: 107 - 108 *

Also Published As

Publication number Publication date
MX2018007415A (es) 2018-11-09
KR20180085814A (ko) 2018-07-27
BR112018012325A2 (pt) 2018-12-04
MX2020012771A (es) 2022-10-04
IL259557A (en) 2018-07-31
JP6940504B2 (ja) 2021-09-29
US20190241527A1 (en) 2019-08-08
EP3390368A4 (en) 2019-07-03
JP2021191782A (ja) 2021-12-16
US10766868B2 (en) 2020-09-08
AU2021202610B2 (en) 2022-06-02
AU2016369520A1 (en) 2018-06-07
CA3006077A1 (en) 2017-06-22
EA201891431A1 (ru) 2018-11-30
EP3390368A1 (en) 2018-10-24
SG11201804601TA (en) 2018-07-30
US20170174637A1 (en) 2017-06-22
US11279679B2 (en) 2022-03-22
JP2018537495A (ja) 2018-12-20
TW201733992A (zh) 2017-10-01
TWI748972B (zh) 2021-12-11
WO2017106639A1 (en) 2017-06-22
CN108602779A (zh) 2018-09-28
AU2016369520B2 (en) 2021-02-18
US9834519B2 (en) 2017-12-05
US20180065937A1 (en) 2018-03-08
NZ742785A (en) 2023-06-30
US10093632B2 (en) 2018-10-09
US20200102276A1 (en) 2020-04-02
HK1255014A1 (zh) 2019-08-02
EP4015508A1 (en) 2022-06-22
AU2021202610A1 (en) 2021-05-27
MX385672B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
US11279679B2 (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
US12234239B2 (en) Crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile
EP4092037A1 (en) Co-crystals, salts and solid forms of tenofovir alafenamide
WO2020221006A1 (zh) 一种bet蛋白抑制剂、其制备方法及用途
JP6916562B2 (ja) 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤
US10717710B2 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds
WO2024020409A1 (en) Therapeutic compounds, formulations, and use thereof
HK40079039A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
US20200039967A1 (en) Novel forms of afatinib dimaleate
EA042753B1 (ru) Способы получения полиморфа дигидрохлорида замещенного 5,6-дигидро-6-фенилбензо[f]изохинолин-2-амина
JP2011515493A (ja) 抗原受容体により誘導されるＮＦ−κＢの活性化の阻害剤
HK40079038A (en) Method of preparing solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
HK40083474A (en) Co-crystals, salts and solid forms of tenofovir alafenamide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220809

WD01 Invention patent application deemed withdrawn after publication